Needham analyst David Saxon reiterated a Buy rating on Alphatec Holdings today and set a price target of $25.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Saxon has given his Buy rating due to a combination of factors, including Alphatec’s in-line fourth-quarter 2025 revenue performance relative to its prior update and management’s decision to lift 2026 adjusted EBITDA guidance, which signals improved profitability expectations. He also notes that the company’s base of active surgeons expanded by roughly 23% to about 1,700, underscoring strong commercial adoption and increased procedural volume potential.
Additionally, Saxon highlights that Alphatec’s lateral spine portfolio is gaining traction, with market share advancing to roughly 20% in 2025, about five percentage points higher than the prior year. With operational trends staying solid into 2026 and more than 30% of incremental revenue flowing through to adjusted EBITDA, he views the company’s earnings leverage and growth profile as compelling, making the current valuation an attractive risk/reward and supporting his Buy recommendation.
In another report released yesterday, TD Cowen also assigned a Buy rating to the stock with a $20.00 price target.